Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (471)	10/22/2001 2:16:44 PM
From: tuck	Read Replies (1) \| Respond to of 1005

>>TOKYO and MADISON, Wis., Oct. 22 /PRNewswire/ -- Third Wave Technologies Inc. (Nasdaq: TWTI - news) and Otsuka Pharmaceutical Co. Ltd. today announced that they have signed a major marketing and distribution agreement. Under the agreement, Third Wave appointed Otsuka as its exclusive distributor for Invader® research products in Japan and other countries in the Far East, Southeast Asia and the Middle East that together comprise approximately 25 percent of the world market for genome research tools. Otsuka is a leading provider of pharmaceuticals, medical devices, genome research products and other healthcare products. Otsuka Group and its overseas affiliates have 23,000 employees and had gross sales of approximately $8 billion in 2000. Otsuka is a prominent member of the Pharma SNP Consortium, created by the Japanese pharmaceutical industry to fund pharmacogenomic research in close collaboration with Japan's Millennium Project. The partnership of Third Wave with Otsuka will further accelerate Third Wave's market penetration in Japan, which is emerging as the largest and most robust market for SNP analysis products through its world leadership in SNP-disease association studies. The agreement is incremental to Third Wave's existing collaboration with the Japanese government's Millennium Project. Under that collaboration, Third Wave is supplying more than 120,000 Invader single nucleotide polymorphism (SNP) assay products to the largest SNP-disease association study in the world. Otsuka will market, distribute and provide technical support for both existing catalog and new custom-order Invader® products for genotyping and gene expression analysis. Third Wave has more than 80,000 SNP genotyping products available now and is adding more than 6,000 new such products to its catalog every month. Third Wave also has designed more than 1.7 million Invader® SNP analysis products covering almost all of the known SNPs. These products are available by custom order. In addition, Third Wave recently launched its first installment of a large menu of Invader® gene expression products. ``Otsuka is very pleased to be Third Wave's partner and exclusive distributor because we believe strongly that the Invader® product platform will become the standard for genetic analysis,'' said Kazuhiro Tomita, Managing Director of Otsuka. ``The Invader® product platform's performance, ease of use, cost-effectiveness and proven transferability from the research lab to the clinic is driving its adoption as the genetic analysis tool of choice and is making personalized medicine a reality.'' ``Otsuka is a worldwide leader in health care and Third Wave is very pleased to have them as our partner,'' said Lance Fors, Ph.D., chairman and chief executive officer of Third Wave. ``Third Wave's partnership with Otsuka solidifies our leadership position in Japan and significantly expands and expedites our business opportunities throughout Asia.'' The territory covered by the agreement includes, in addition to Japan, China, South Korea, Thailand, Indonesia, the Philippines, Egypt and Pakistan.<< snip Cheers, Tuck

To: Jibacoa who wrote (471)	10/22/2001 4:49:00 PM
From: Jibacoa	Respond to of 1005

AGIX: Looking at AGIX stock on Oct.5 (the day of the "downgrades" <g>)On the 60 minutes chart, it is noticeably that the initial "drop" (from the 4.00 close on Oct.4 to the L of 2.23 on the first hour of trading)took place on a volume of 356,500<g> In the next half hour the volume was 2,156,600 with the price going from 2.25 to 2.60<g> Since then the only other "significant"<g> volume was on the first half hour of trading on Oct.10 (479,400)(and the price then O=2.95 H=3.06 L=2.86 C=2.99) On Oct. 5 in spite of the fact that the price closed below the Oct.4 close, there was a "significant"<g> positive "money flow". marketwatch.com siliconinvestor.com Bernard